The EDGE

Myelofibrosis, JAK2 inhibitors and erythropoiesis

W Vainchenker and F Favale

Leukemia 2013 27: 1219-1223; 10.1038/leu.2013.72

Review

In focus: MLL-rearranged leukemia

J de Boer, V Walf-Vorderwülbecke and O Williams

Leukemia 2013 27: 1224-1228; advance online publication, March 21, 2013; 10.1038/leu.2013.78

Original Articles

THERAPY

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

T Schroeder, A Czibere, U Platzbecker, G Bug, L Uharek, T Luft, A Giagounidis, F Zohren, I Bruns, C Wolschke, K Rieger, R Fenk, U Germing, R Haas, N Kröger and G Kobbe

Leukemia 2013 27: 1229-1235; advance online publication, January 14, 2013; 10.1038/leu.2013.7

Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity

P A Spagnuolo, R Hurren, M Gronda, N MacLean, A Datti, A Basheer, F-H Lin, X Wang, J Wrana and A D Schimmer

Leukemia 2013 27: 1236-1244; advance online publication, January 15, 2013; 10.1038/leu.2013.9

ACUTE LEUKEMIAS

Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75)

H Méreau, J De Rijck, K Čermáková, A Kutz, S Juge, J Demeulemeester, R Gijsbers, F Christ, Z Debyser and J Schwaller

Leukemia 2013 27: 1245-1253; advance online publication, January 15, 2013; 10.1038/leu.2013.10

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, D Beelen, V Vucinic, T Burmeister, M Stelljes, C Faul, P Dreger, A Kiani, K Schäfer-Eckart, R Schwerdtfeger, E Lange, B Kubuschok, H A Horst, M Gramatzki, P Brück, H Serve, D Hoelzer, N Gökbuget and O G Ottmann on behalf of the GMALL Study Group

Leukemia 2013 27: 1254-1262; advance online publication, December 5, 2012; 10.1038/leu.2012.352

Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

K Matlawska-Wasowska, E Ward, S Stevens, Y Wang, R Herbst, S S Winter and B S Wilson

Leukemia 2013 27: 1263-1274; advance online publication, January 11, 2013; 10.1038/leu.2013.5

MYELODYSPLASIAS

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

M J Walter, D Shen, J Shao, L Ding, B S White, C Kandoth, C A Miller, B Niu, M D McLellan, N D Dees, R Fulton, K Elliot, S Heath, M Grillot, P Westervelt, D C Link, J F DiPersio, E Mardis, T J Ley, R K Wilson and T A Graubert

Leukemia 2013 27: 1275-1282; advance online publication, February 27, 2013; 10.1038/leu.2013.58

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

C Kelaidi, S Park, R Sapena, O Beyne-Rauzy, V Coiteux, N Vey, A Stamatoullas, B Choufi, J Delaunay, M-P Gourin, S Cheze, C Ravoet, A Ferrant, M Escoffre-Barbe, L Aljassem, E Raffoux, R Itzykson, L Adès, F Dreyfus and P Fenaux on behalf of the Groupe Francophone des Myélodysplasies (GFM)

Leukemia 2013 27: 1283-1290; advance online publication, January 16, 2013; 10.1038/leu.2013.16

Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome

J X Cheng, J Anastasi, K Watanabe, E L Kleinbrink, E Grimley, R Knibbs, Q J Shen and J W Vardiman

Leukemia 2013 27: 1291-1300; advance online publication, February 15, 2013; 10.1038/leu.2013.45

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

S N Khan, A M Jankowska, R Mahfouz, A J Dunbar, Y Sugimoto, N Hosono, Z Hu, V Cheriyath, S Vatolin, B Przychodzen, F J Reu, Y Saunthararajah, C O'Keefe, M A Sekeres, A F List, A R Moliterno, M A McDevitt, J P Maciejewski and H Makishima

Leukemia 2013 27: 1301-1309; advance online publication, March 14, 2013; 10.1038/leu.2013.80

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

F J Giles, M J Mauro, F Hong, C-E Ortmann, C McNeill, R C Woodman, A Hochhaus, P D le Coutre and G Saglio

Leukemia 2013 27: 1310-1315; advance online publication, March 5, 2013; 10.1038/leu.2013.69

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T D Kim, D Rea, M Schwarz, P Grille, F E Nicolini, G Rosti, L Levato, F J Giles, H Dombret, T Mirault, H Labussière, R Lindhorst, W Haverkamp, I Buschmann, B Dörken and P D le Coutre

Leukemia 2013 27: 1316-1321; advance online publication, March 5, 2013; 10.1038/leu.2013.70

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis Open

A Pardanani, R R Laborde, T L Lasho, C Finke, K Begna, A Al-Kali, W J Hogan, M R Litzow, A Leontovich, M Kowalski and A Tefferi

Leukemia 2013 27: 1322-1327; advance online publication, March 5, 2013; 10.1038/leu.2013.71

IMMUNOLOGY

γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia

W Scheper, S van Dorp, S Kersting, F Pietersma, C Lindemans, S Hol, S Heijhuurs, Z Sebestyen, C Gründer, V Marcu-Malina, A Marchant, C Donner, B Plachter, D Vermijlen, D van Baarle and J Kuball

Leukemia 2013 27: 1328-1338; advance online publication, January 1, 2013; 10.1038/leu.2012.374

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION

AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL

M J Stankiewicz and J D Crispino

Leukemia 2013 27: 1339-1347; advance online publication, February 5, 2013; 10.1038/leu.2013.33

Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia Open

S H Oram, J Thoms, J I Sive, F J Calero-Nieto, S J Kinston, J Schütte, K Knezevic, R B Lock, J E Pimanda and B Göttgens

Leukemia 2013 27: 1348-1357; advance online publication, January 10, 2013; 10.1038/leu.2013.2

APOPTOSIS

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

L Zhou, V R Ruvolo, T McQueen, W Chen, I J Samudio, O Conneely, M Konopleva and M Andreeff

Leukemia 2013 27: 1358-1368; advance online publication, December 18, 2012; 10.1038/leu.2012.366

DIFFERENTIATION

ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells

L C Y Chee, J Hendy, L E Purton and G A McArthur

Leukemia 2013 27: 1369-1380; advance online publication, December 11, 2012; 10.1038/leu.2012.362

LYMPHOMA

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

S-S Wenzel, M Grau, C Mavis, S Hailfinger, A Wolf, H Madle, G Deeb, B Dörken, M Thome, P Lenz, S Dirnhofer, F J Hernandez-Ilizaliturri, A Tzankov and G Lenz

Leukemia 2013 27: 1381-1390; advance online publication, December 21, 2012; 10.1038/leu.2012.367

MYELOMA

Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients

L E Roeker, D R Larson, R A Kyle, S Kumar, A Dispenzieri and S V Rajkumar

Leukemia 2013 27: 1391-1393; advance online publication, February 5, 2013; 10.1038/leu.2013.34

Letters to the Editor

Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology

S-W Kim, S-S Yoon, R Suzuki, Y Matsuno, H G Yi, T Yoshida, M Imamura, A Wake, K Miura, M Hino, T Ishikawa, J S Kim, Y Maeda, J-J Lee, H J Kang, H S Lee, J-H Lee, K Izutsu, T Fukuda, C W Kim, T Yoshino, K Ohshima, S Nakamura, K Nagafuji, J Suzumiya, M Harada and C S Kim

Leukemia 2013 27: 1394-1397; advance online publication, November 27, 2012; 10.1038/leu.2012.321

A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1

L Solari, T Bauer, F Dicker, C Haferlach, M Grießhammer, S Schnittger, H Becker and M Lübbert

Leukemia 2013 27: 1397-1400; advance online publication, February 21, 2013; 10.1038/leu.2013.53

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

F Damm, R Itzykson, O Kosmider, N Droin, A Renneville, V Chesnais, V Gelsi-Boyer, S de Botton, N Vey, C Preudhomme, A Clavert, E Delabesse, S Park, D Birnbaum, M Fontenay, O A Bernard and E Solary

Leukemia 2013 27: 1401-1403; advance online publication, February 5, 2013; 10.1038/leu.2013.35

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study Open

U Platzbecker, F Braulke, A Kündgen, K Götze, G Bug, C Schönefeldt, K Shirneshan, C Röllig, M Bornhäuser, R Naumann, J Neesen, A Giagounidis, W-K Hofmann, G Ehninger, U Germing, D Haase and M Wermke on behalf of the German MDS Study Group

Leukemia 2013 27: 1403-1407; advance online publication, January 28, 2013; 10.1038/leu.2013.26

Lenalidomide-induced upregulation of CXCR4 in CD34⁺ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization

S Li, J Fu, H Ma, M Y Mapara and S Lentzsch

Leukemia 2013 27: 1407-1411; advance online publication, November 9, 2012; 10.1038/leu.2012.323

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia

O G Ottmann, R A Larson, H M Kantarjian, P D le Coutre, M Baccarani, A Hochhaus, D W Kim, X Fan, S Novick and F J Giles

Leukemia 2013 27: 1411-1413; advance online publication, November 9, 2012; 10.1038/leu.2012.324

Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1

D O Croci, P E Morande, S Dergan-Dylon, M Borge, M A Toscano, J C Stupirski, R F Bezares, J S Avalos, M Narbaitz, R Gamberale, G A Rabinovich and M Giordano

Leukemia 2013 27: 1413-1416; advance online publication, November 7, 2012; 10.1038/leu.2012.315

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD⁺ AML but retains in vitro sensitivity to PKC412 and Sunitinib

C Albers, H Leischner, M Verbeek, C Yu, A L Illert, C Peschel, N von Bubnoff and J Duyster

Leukemia 2013 27: 1416-1418; advance online publication, January 16, 2013; 10.1038/leu.2013.14

A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma

K J Thomson, I Kayani, K Ardeshna, E C Morris, R Hough, A Virchis, A H Goldstone, D C Linch and K S Peggs

Leukemia 2013 27: 1419-1422; advance online publication, November 8, 2012; 10.1038/leu.2012.318

Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion

E De Braekeleer, N Douet-Guilbert, P Guardiola, D Rowe, S Mustjoki, A Zamecnikova, S Al Bahar, G Jaramillo, C Berthou, N Bown, K Porkka, C Ochoa and M De Braekeleer

Leukemia 2013 27: 1422-1424; advance online publication, November 20, 2012; 10.1038/leu.2012.332

Secondary mutations in t(4;11) leukemia patients Open

C Prelle, A Bursen, T Dingermann and R Marschalek

Leukemia 2013 27: 1425-1427; advance online publication, December 14, 2012; 10.1038/leu.2012.365

Low GFI1 expression in white blood cells of CP–CML patients at diagnosis is strongly associated with subsequent blastic transformation

C H Kok, D B Watkins, T Leclercq, R J D'Andrea, T P Hughes and D L White

Leukemia 2013 27: 1427-1430; advance online publication, February 15, 2013; 10.1038/leu.2013.47

Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study

A Pardanani, C Finke, R A Abdelrahman, T L Lasho, C A Hanson and A Tefferi

Leukemia 2013 27: 1430-1433; advance online publication, January 15, 2013; 10.1038/leu.2013.11

Direct binding of Grb2 has an important role in the development of myeloproliferative disease induced by ETV6/FLT3

K Chonabayashi, M Hishizawa, S Kawamata, Y Nagai, T Ohno, T Ishikawa, T Uchiyama and A Takaori-Kondo

Leukemia 2013 27: 1433-1436; advance online publication, November 20, 2012; 10.1038/leu.2012.333

Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts

A J Yost, O O Shevchuk, R Gooch, S Gusscott, M J You, T A Ince, J C Aster and A P Weng

Leukemia 2013 27: 1437-1440; advance online publication, November 21, 2012; 10.1038/leu.2012.337